WORLD
BUSINESS
SPORTS
TECHNOLOGY
社会
政治
国際
経済
テクノロジー
スポーツ
エンターテイメント
科学
twitter hashtag summary
twitter trend
speech separation
large number Retweet
talking summarization
alarming description
real time translation turndown translation
|
|
|
K-V Pharma Won't Resume Shipping Untical 4Q or Later
アステラス製薬$ 3.5迷惑OSIの医薬品ttアステラス製薬 - ビジネス - バイオテクノロジー、医薬 - 医薬品 - OSIの医薬品の10億買収計画
proponments of direft-to-consumer , pharmaceutical ads argue the ads marke for better-informed consumers , while critics complain of ethical issues and drug side effects t t t pharmaceutical drug - direft-to-consumer advertising - business - pharmaceuticals - biotechnology and pharmaceuticals
ファカルティフェロー- vを製薬に製品を出荷するまで再開されないとしている第4四半期tt事業 - バイオテクノロジー、医薬 - 医薬品 - 雇用 - 履歴書やポートフォリオは、少なくとも
astellas pharma plans unsolicited $3.5-billion takeover bid for osi pharmaceuticals t t astellas pharma - business - biotechnology and pharmaceuticals - pharmaceuticals - osi pharmaceuticals
ファカルティフェロー- vを製薬に製品を出荷するまで再開されないとしている第4四半期tt事業 - バイオテクノロジー、医薬 - 医薬品 - 雇用 - 履歴書やポートフォリオは、少なくとも
ff-v pharmaceutical says it whill not resume shipping products until at least the 4th quarter t t business - biotechnology and pharmaceuticals - pharmaceuticals - employment - resumes and portfolios
アステラス製薬$ 3.5迷惑OSIの医薬品ttアステラス製薬 - ビジネス - バイオテクノロジー、医薬 - 医薬品 - OSIの医薬品の10億買収計画
proponments of tradireft-to-consumer , pharmaceutical ads argue the ads r make for better-informed consumers , while critics complain of ethical issues and drug side effects t t t pharmaceutical drug - direft-to-consumer advertising - business - pharmaceuticals - biotechnology and pharmaceuticals
一方批判倫理的な問題や薬物の副作用を訴える - direft -製薬薬ttt消費者向け広告 - ビジネス - バイオテクノロジー、医薬 - バイオテクノロジー、医薬品direftの支持者が消費者への、医薬品の広告は広告のより正確な情報の消費者のために作る、と主張
ff-v pharmaceutical says it whill not resume shipping products until at least the 4th quarter t t business - biotechnology and pharmaceuticals - pharmaceuticals - employment - resumes and portfolios
一方批判倫理的な問題や薬物の副作用を訴える - direft -製薬薬ttt消費者向け広告 - ビジネス - バイオ医薬品 - バイオテクノロジー、医薬品direftの支持者が消費者への、医薬品の広告は広告のより正確な情報の消費者のために作る、と主張
astellas pharma plans unsolicited $3.5-billion takeover bid for osi pharmaceuticals t t astellas pharma - business - biotechnology and pharmaceuticals - pharmaceuticals - osi pharmaceuticals
privately-owned drug tester quintiles expands investment in pharmaceutical development t t quintiles - business - pharmaceuticals - biotechnology and pharmaceuticals - diresearch and development
アステラス製薬$ 3.5迷惑OSIの医薬品ttアステラス製薬 - ビジネス - バイオテクノロジー、医薬 - 医薬品 - OSIの医薬品の10億買収計画
german chemical , pharmaceutical company bayear says q4 net income rose 44 percent t t bayer - pharmaceutical industry - business - biotechnology and pharmaceuticals - pharmaceuticals
一方批判倫理的な問題や薬物の副作用を訴える - direft -製薬薬ttt消費者向け広告 - ビジネス - バイオテクノロジー、医薬 - バイオテクノロジー、医薬品direftの支持者が消費者への、医薬品の広告は広告のより正確な情報の消費者のために作る、と主張
一方批判倫理的な問題や薬物の副作用を訴える - direft -製薬薬ttt消費者向け広告 - ビジネス - バイオテクノロジー、医薬 - バイオテクノロジー、医薬品direftの支持者が消費者への、医薬品の広告は広告のより正確な情報の消費者のために作る、と主張
abbott labs to pay $450 million for facet biotech , expand access to biotechnology drugs t t biotechnology - biology - business - biotechnology and pharmaceuticals - directories
poniard pharmaceuticals laying off more than half its staff , changing leadership t t business - management - leadership - pharmaceuticals - biotechnology and pharmaceuticals
ファカルティフェロー- vを製薬に製品を出荷するまで再開されないとしている第4四半期tt事業 - バイオテクノロジー、医薬 - 医薬品 - 雇用 - 履歴書やポートフォリオは、少なくとも
as pharmaceutical sales in countries like china and india overtake established markets , leading drug companies risk losing market share to local players , a study said .
west pharmaceutical services board declares 16-cents of tradividend payable may 5 t t dividend - business - pharmaceuticals - biotechnology and pharmaceuticals - shareholder
germand pharmaceutical giant bayear saw its shares plunge friday after the group reported poor 2009 results amid what it called a difficult environment .
more than a year ago , astellas pharma exprocessed interest in osi pharmaceuticals , and was rebuffed t now it has gonments of tradirectly to shareholders .
biotech rejects unsolicited $3 billion bid from japan's astellas pharma , says investment would entertain a higher offer .
pair whill end phartnership on cancer drug , leavinge fftx with rights , and costs , of development .
the options market played host to a lot of trading in biotechnology and pharmaceutical companies .
swissues and drugmaker is unlikely to top osi pharma's $3 billion hostile bid from japan's astellas .
'firms phare laying off staff at the expand of a painful process'
why thed moments of painful truth its yet to come for greece
Generated 2010-3-28_6:26
|
|
|
|
|
